M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
TL;DR: TPDC-FUHU chemotherapy is a highly effective form of chemotherapy for both recurrent GM and AG patients and this combination may be superior to other NU-based treatments for recurrent malignant glioma patients who fail RT.
Journal ArticleDOI
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
Lakshmi Nayak,Lauren E. Abrey,Jan Drappatz,Mark R. Gilbert,David A. Reardon,Patrick Y. Wen,Michael D. Prados,Lisa M. DeAngelis,Antonio Omuro +8 more
TL;DR: Treatment was well tolerated, but due to slow accrual and preliminary analysis suggesting futility, the trial was closed early and given the overall modest activity, this regimen should be reserved for patients who are not candidates for other, more aggressive salvage treatments.
Journal ArticleDOI
Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
Timothy F. Cloughesy,John G. Kuhn,H. Ian Robins,Lauren E. Abrey,Patrick Y. Wen,Karen Fink,Frank S. Lieberman,Minesh P. Mehta,Susan M. Chang,Alfred Yung,Lisa M. DeAngelis,David Schiff,Larry Junck,Morris D. Groves,Steve Paquette,John Tim Wright,Kathleen R. Lamborn,Said M. Sebti,Michael D. Prados +18 more
TL;DR: Toxicities and pharmacokinetics differ significantly when comparing patients on or off EIAEDs, and even in the presence of EIAeds, the levels of tipifarnib were still sufficient to potently inhibit FTase activity in patient PBMCs.
Journal ArticleDOI
Interstitial irradiation and hyperthermia for the treatment of recurrent malignant brain tumors.
Penny K. Sneed,Paul R. Stauffer,Philip H. Gutin,T.L. Phillips,S. A. Suen,Keith A. Weaver,Sharon Lamb,Brigid Ham,Michael D. Prados,David A. Larson +9 more
TL;DR: It is concluded that interstitial brain hyperthermia using helical coil microwave antennas is technically feasible and the level of toxicity is acceptable, and the computed tomographic response rate is encouraging.
Journal ArticleDOI
Treatment of Recurrent Gliomas With Eflornithine
Victor A. Levin,Michael D. Prados,W. K. Alfred Yung,Mary Jo Gleason,Sandra Ictech,Mary Malec +5 more
TL;DR: It is suggested that eflornithine alone is an effective palliative therapy for recurrent anaplastic gliomas and additional studies are needed to confirm this finding.